Paliogiannis P, Cossu A, Capobianco G, Sini M C, Palomba G, Virdis G, Dessole M, Palmieri G
Eur J Gynaecol Oncol. 2014;35(1):72-6.
Mature cystic teratoma (MCT) is the most frequent ovarian tumor and it is generally composed of well-differentiated elements which, nevertheless, have the potential for malignant transformation. The authors report two cases of squamous cell carcinoma (SCC) arising on ovarian MCT. In the present study, no mutation of the CDKN2A gene, whose impairment may deeply affect either the p16(CDKN2A)-CyclinD1-pRb cascade or the p14(CDKN2A)-mdm2-p53 cascade, was observed in tumour tissues from our cases' collection. This suggests that changes in the protein levels for the above-described candidate effectors may be somehow due to epigenetic alterations into the mechanisms controlling their expression. Analogously, no genetic modification among the two main genes (EGFR and KRAS) upstream the MAPK signalling pathway, which has been widely reported to play a major role in both development and progression of vast majority of malignant tumours, was detected in this series. Additional genes and pathways should be therefore investigated in order to identify genomic impairments underlying the MCT malignant transformation.
成熟囊性畸胎瘤(MCT)是最常见的卵巢肿瘤,通常由分化良好的成分组成,然而,这些成分具有恶性转化的潜力。作者报告了两例起源于卵巢MCT的鳞状细胞癌(SCC)病例。在本研究中,在我们收集的病例的肿瘤组织中未观察到CDKN2A基因的突变,该基因的损伤可能会深刻影响p16(CDKN2A)-细胞周期蛋白D1-pRb级联反应或p14(CDKN2A)-mdm2-p53级联反应。这表明上述候选效应蛋白的蛋白质水平变化可能在某种程度上是由于控制其表达的机制发生了表观遗传改变。类似地,在该系列中未检测到丝裂原活化蛋白激酶(MAPK)信号通路上游的两个主要基因(表皮生长因子受体(EGFR)和 Kirsten 大鼠肉瘤病毒癌基因(KRAS))的基因修饰,该信号通路在绝大多数恶性肿瘤的发生和发展中都起着重要作用。因此,应该研究其他基因和信号通路,以确定MCT恶性转化背后的基因组损伤。